Evidence map›Paper›PMID 37891002›Full record

ArticleLife science alliance2024

APR-246 increases tumor antigenicity independent of p53.

Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam M George, Daniel Thach, Zhong-Ke Yao, Ouathek Ouerfelli, Hengrui Liu and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Judith MichelsDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-9640-0222
Divya VenkateshDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Cailian LiuDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Sadna BudhuDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Hong ZhongDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Mariam M GeorgeDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Daniel ThachDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-7609-8775
Zhong-Ke YaoThe Organic Synthesis Core Facility, MSK, New York, NY, USA.ORCID https://orcid.org/0000-0002-0427-686X
Ouathek OuerfelliThe Organic Synthesis Core Facility, MSK, New York, NY, USA.ORCID https://orcid.org/0000-0002-7038-0219
Hengrui LiuDepartment of Biological Sciences, Columbia University, New York, NY, USA.ORCID https://orcid.org/0000-0002-5214-1572
Brent R StockwellDepartment of Biological Sciences, Columbia University, New York, NY, USA.
Luis Felipe CampesatoDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
Dmitriy ZamarinSwim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roberta ZappasodiDepartment of Medicine, Weill Cornell, New York, NY, USA.ORCID https://orcid.org/0000-0002-7031-6671
Jedd D WolchokDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA jwolchok@med.cornell.edu.ORCID https://orcid.org/0000-0001-6718-2222
Taha MerghoubDepartment of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA tmerghoub@med.cornell.edu.ORCID https://orcid.org/0000-0002-1518-5111
Cornell University · USColumbia University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly. MQ treatment of murine B16F10 melanoma cells promoted activation of melanoma-specific CD8

Indexed as

CD8-Positive T-LymphocytesMelanomaAnimalsAntigens, NeoplasmMiceTumor Suppressor Protein p53Antigens, NeoplasmTumor Suppressor Protein p53

Identifiers

PMID37891002
PMCPMC10610029
OpenAlexW4387996199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.